# US 2003/0073659 A1 · Adeno associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal DNA of target cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0073659 A1
- Document ID: US20030073659A1
- Status: Published application
- Kind: A1
- Application number: 10/196,688
- Filed: 2002-07-15
- Published: 2003-04-17
- Earliest claimed: 1997-12-23
- Inventors: Markus Peter Einerhand; Domenico Valerio; Govert Johan Schouten
- Web page: https://patentgrep.com/patent/US20030073659A1

## CPC

- C12N 15/86: Viral vectors
- C12N 2710/10322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2710/10344: Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2830/38: being a stuffer
- C12N 2830/42: being an intron or intervening sequence for splicing and/or stability of RNA
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Chimeric viral vectors having both the capacity to infect host cells efficiently and the capacity to integrate their genomic material into the host cell's genome. A chimeric viral vector having a functional packaging signal derived from a first virus and an integration means derived from a second virus. Typically, viruses capable of integrating their material into a host cell genome, having additional genetic material introduced therein recombinantly, do not have much room for insertion of such additional genetic material or are not very well capable of infecting every wanted host cell. Infecting viruses also lack a high insertion capacity or integration into the host cell's genome. The present invention provides integration of large inserts into a host cell's genome at an efficient infection rate by combining the properties of efficiently infecting viruses with efficiently integrating viruses.

## Claims

### Claim 1

A chimeric viral vector comprising:
a functional packaging signal derived from a first virus having no integration means; and
an integration means derived from a second, integrating virus.

### Claim 2 (depends on 1)

The chimeric viral vector of claim 1, wherein the first virus is a virus capable of efficiently infecting a host.

### Claim 3 (depends on 1, 2)

The chimeric viral vector of claim 1 or 2, wherein the first virus is an adenovirus.

### Claim 4 (depends on 1, 2, 3)

The chimeric viral vector of claim 1, claim 2, or claim 3 wherein the second, integrating virus is an adeno associated virus.

### Claim 5 (depends on 4)

The chimeric viral vector of claim 4, further comprising a sequence encoding a functional adeno associated virus rep gene.

### Claim 6 (depends on 2, 3, 4, 5)

The chimeric viral vector of claiml, claim 2, claim 3, claim 4 or claim 5 further comprising a nucleic acid sequence of interest.

### Claim 7 (depends on 6)

The chimeric viral vector of claim 6, wherein the nucleic acid sequence of interest comprises one or more genes.

### Claim 8 (depends on 6)

The chimeric viral vector of claim 6, wherein the nucleic acid sequence of interest encodes a sequence chosen from a group consisting of antisense sequences and co-suppressing sequences.

### Claim 9 (depends on 6, 7, 8)

The chimeric viral vector of claim 6, claim 7, or claim 8 further comprising regulatory elements for expressing the nucleic acid sequence of interest.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The chimeric viral vector of claim 1, claim 2, claim 3, claim 4, claim 5, claim 6, claim 7, claim 8, or claim 9 further comprising a suicide gene.

### Claim 11

A virus-like particle comprising a chimeric viral vector, the chimeric viral vector comprising:
a functional packaging signal derived from a first virus having no integration means; and
an integration means derived from a second, integrating virus.

### Claim 12 (depends on 11)

The virus-like particle of claim 11, further comprising an adenovirus-like particle.

### Claim 13

A method for producing a virus-like particle comprising a chimeric viral vector, the method comprising:
providing a cell with viral vector comprising
a functional packaging signal derived from a first virus having no integration means, and
an integration means derived from a second, integrating virus; and
providing said cell with elements necessary for producing said virus-like particle.

### Claim 14 (depends on 13)

The method according to claim 13, wherein a first element of said elements necessary for production of said virus-like particle is present in said vector and a second element of said elements necessary for production of said virus-like particle is present in a packaging vector present in said cell.

### Claim 15 (depends on 13)

The method according to claim 13, wherein said elements necessary for production of said virus-like particle are present on a packaging vector present in said cell.

### Claim 16

A packaging cell comprising genetic elements resulting in production of a virus-like particle including a chimeric viral vector having a functional packaging signal derived from a first virus lacking an integration means and an integration means derived from a second, integrating virus.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 16)

The packaging cell of claim 16 further comprising the vector according to any one of claims 1-10.

### Claim 18

A cell comprising:
a chimeric viral vector comprising a functional packaging signal derived from a first virus lacking integration means and an integration means derived from a second, integrating virus.

### Claim 19 (depends on 11, 12)

A virus-like particle according to claim 11 or 12 for use as a pharmaceutical.

### Claim 20

A method for treatment of a host, said method comprising:
providing a host exhibiting a dysfunction selected from a group consisting of inherited diseases, malignancies, and genetic deficiencies;
providing a virus-like particle comprising a chimeric viral vector including a functional packaging signal derived from a first virus having no integration means and an integration means derived from a second, integrating virus; and
introducing said virus-like particle into said host.

### Claim 21 (depends on 11, 12)

The virus-like particle of claim 11 or 12 for use as a means for permanent genetic modification of a cell.

### Claim 22 (depends on 11, 12)

The virus-like particle of claim 11 or 12 for use as a means for making transgenic organisms.

### Claim 23

An rAAV nucleic acid comprising a nucleic acid sequence larger than 6.5 kb flanked by and physically linked with two ITRs, each of said two ITRs comprising an ITR selected from a group consisting of an AAV-ITR, a functional part of an AAV-ITR, and a derivative of an AAV-ITR.

### Claim 24

A method for the replication of an rAAV nucleic acid, the method comprising:
providing a cell with proteins encoded by at least a portion of an AAV-rep gene, at least a portion of a protein encoded by an adenovirus region selected from a group of adenovirus regions consisting of E1 regions, E2 regions, and E4 regions; and
providing said cell with a nucleic acid comprising an rAAV nucleic acid larger than 6.5 kb and being flanked by two AAV-ITR.

### Claim 25 (depends on 24)

The method according to claim 24, wherein providing said cell comprises providing a cell further comprising RNA encoded by at least a portion of an adenovirus VA-region.
